Multiple myeloma

There are 241 papers on multiple myeloma in aging research: 14 trials and 144 observational studies in people, 12 in animals, 7 in cells, 48 reviews. The newest story, Nov 19, 2026: “Immune aging score linked to shorter myeloma survival”.

Disease

241 papers study it68 more mention it45 findings

MeSH

15 new papers in 30 daysSee all 309 papers on multiple myeloma

At a glance

Human studies link multiple myeloma with bone-marrow cellular senescence, frailty changes and gait-speed decline. Myeloma is associated with higher dementia risk during the first three years. A study of patients of African ancestry shows no clear epigenetic-age difference between myeloma and MGUS.

45 findings in 32 papers from 1996 to 2026, 6 of them since May 2026

“we found a higher risk for Hodgkin lymphoma, multiple myeloma and amyotrophic lateral sclerosis”
The selenium and vitamin E cancer prevention trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administrationAmerican journal of epidemiology2026doi:10.1093/aje/kwag189
  • Human trial14
  • Humans144
  • Animals12
  • Cells7
  • In silico8

Interventions

2

Dietary glycemic load

no changein humans1OR 1.37

1 study
  1. Dietary glycemic load was not clearly linked with multiple myeloma in humans (Iranian population; fully adjusted model) (OR 1.37, 95% CI 0.51–3.63; P-trend = 0.45).

    “GL was not associated with MM in the fully adjusted model (OR 1.37, 95% CI 0.51–3.63; P-trend = 0.45).”

    HumansIranian population; fully adjusted model

    Association of glycemic index and glycemic load with multiple myeloma: a case–control study

    Scientific reports

More on Dietary glycemic load

Radon

no changein humans1

1 study
  1. Radon was not clearly linked with multiple myeloma in humans.

    “Based on 5218 included patients distributed among 275 municipalities, no statistically significant association was found.”

    Humansn = 5,218

    The risk of multiple myeloma associated with daily low-dose exposure to ionising radiation from radon decay

    Cancer epidemiology

More on Radon

Effects

6

Epigenetic age

no changein humans1

1 study
  1. Multiple myeloma was not clearly linked with epigenetic age in humans (Multiple myeloma versus MGUS in patients of African ancestry).

    “epigenetic age acceleration did not differ between groups”

    HumansMultiple myeloma versus MGUS in patients of African ancestry

    Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry

    Cells

More on Epigenetic age

Mature neutrophils

upin human cells1

1 study
  1. Multiple myeloma increases mature neutrophils in MM patients.

    “developmental profiling of BM neutrophils via cytomorphology and flow cytometry revealed a pronounced enrichment of mature neutrophils in MM patients”

    Cellsin MM patientsbone marrow

    Bone Marrow Microenvironment Drives Mature Neutrophil to a CD83 ⁺ Pro-Tumor State in Multiple Myeloma

    International journal of cancer

Mortality

upin humans1

1 study
  1. Multiple myeloma is linked with higher mortality in humans with MM and CVDs (9.6 to 9.9 per 100,000).

    “AAMR increased from 9.6 in 1999 to 9.9 in 2023, with a prominent surge noted between 2018 and 2021 (APC: 6.82).”

    Humanswith MM and CVDs1999 to 2023

    Trends in multiple myeloma and cardiovascular disease-related mortality among older adults in the United States, 1999 to 2023: a CDC wonder database analysis

    Annals of medicine and surgery (2012)

Frailty

upin humans1

1 study
  1. Multiple myeloma increases frailty in multiple myeloma.

    “contributing to the development of a frailty syndrome which impairs the therapeutic impact of recent advances in treatment strategies.”

    Reviewin multiple myeloma

    Immune senescence in multiple myeloma-a role for mitochondrial dysfunction?

    Leukemia

IFNG

downin humans1

1 study
  1. Multiple myeloma is linked with lower IFNG in vitro restimulation.

    “CD8+ T cells from the tumor site failed to produce IFNγ after CD3/CD28 in vitro restimulation”

    Humansin vitro restimulationbone marrow

    T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

    Journal of hematology & oncology

More on IFNG

Inpatient mortality

no changein humans1

1 study
  1. Multiple myeloma was not clearly linked with inpatient mortality in humans.

    “We found that myeloma was not associated with increased inpatient mortality”

    HumansFollowing surgical treatment of hip fractures; compared with patients without multiple myeloma

    Patients With Multiple Myeloma Have More Complications After Surgical Treatment of Hip Fracture

    Geriatric orthopaedic surgery & rehabilitation

Upstream

1

Myeloma Risk Profile

no changein humans1HR 0.99

1 study
  1. Myeloma Risk Profile was not clearly linked with multiple myeloma in humans (elderly newly diagnosed myeloma treated with VCD) (11.8 vs. 9.9 months, HR: 0.99, 95% CI: 0.61-1.61, P = 0.982).

    “There was no difference in median PFS between subgroups: (frail vs. intermediate or fit): (11.8 vs. 9.9 months, HR: 0.99, 95% CI: 0.61-1.61, P = 0.982).”

    Humanselderly newly diagnosed myeloma treated with VCDn = 100

    Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients

    PloS one

More on Myeloma Risk Profile

Associations

34

Monoclonal gammopathy of undetermined significance

upin humans2+1% annually

2 studies
  1. Monoclonal gammopathy of undetermined significance is associated with multiple myeloma in humans (Monoclonal gammopathy of undetermined significance) (8 per 1000 person-years; 0.8% per year (95% CI: 0.7%-1.1%)).

    “8 per 1000 person-years to MM or 0.8% per year (95% CI: 0.7%-1.1%)”

    ReviewMonoclonal gammopathy of undetermined significance

    Rate of MGUS Progression to Haematological Malignancies: A Systematic Review

    European journal of haematology

  2. Monoclonal gammopathy of undetermined significance raises the risk of multiple myeloma in humans (individuals with MGUS) (1% annually).

    “only 1% of individuals with MGUS annually experience progression to MM”

    Reviewindividuals with MGUS

    Immune alterations in myeloma evolution and outcomes: quo vadis?

    Blood

More on Monoclonal gammopathy of undetermined significance

Telomere length

upin silico2OR 1.845

2 studies
  1. Telomere length raises the risk of multiple myeloma in silico (OR = 1.845).

    “multiple myeloma (OR = 1.845; P = 0.024)”

    In silico

    Causality between Telomere Length and the Risk of Hematologic Malignancies: A Bidirectional Mendelian Randomization Study

    Cancer research communications

  2. Telomere length raises the risk of multiple myeloma in silico (OR > 1, P < 0.05).

    “longer telomere lengths significantly increase the risk of multiple myeloma, leukemia, and lymphoma (OR > 1, P < 0.05)”

    In silico

    Mendelian randomization analysis reveals the combined effects of epigenetics and telomere biology in hematologic cancers

    Clinical epigenetics

More on Telomere length

Dietary glycemic index

upin humans1OR 3.92

1 study
  1. Dietary glycemic index is associated with multiple myeloma in humans (Iranian population; fully adjusted for potential confounders) (OR 3.92, 95% CI 1.84–8.34; P-trend < 0.001).

    “Participants in the highest quartile of dietary GI had significantly higher odds of MM compared with those in the lowest quartile”

    HumansIranian population; fully adjusted for potential confoundershighest versus lowest quartile

    Association of glycemic index and glycemic load with multiple myeloma: a case–control study

    Scientific reports

More on Dietary glycemic index

DNAm-estimated telomere length

downin humans1

1 study
  1. Multiple myeloma is associated with DNAm-estimated telomere length in humans.

    “lower DNA methylation (DNAm)-estimated telomere length was observed in MM than in MGUS”

    HumansMultiple myeloma versus MGUS in patients of African ancestry; difference borderline after adjustment for DNAm-estimated blood-cell composition

    Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry

    Cells

More on DNAm-estimated telomere length

DNA methylation

mixedin humans1

1 study
  1. Multiple myeloma is associated with DNA methylation in humans (Multiple myeloma versus MGUS in patients of African ancestry) (703 differentially methylated positions; 122 exploratory candidate regions; one 395 bp RNF39 region spanning 16 CpG sites met FWER significance).

    “DNA methylation profiling identified 703 differentially methylated positions and 122 exploratory candidate differentially methylated regions between MM and MGUS.”

    HumansMultiple myeloma versus MGUS in patients of African ancestry

    Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry

    Cells

More on DNA methylation

VWA5B2

upin humans1

1 study
  1. VWA5B2 is associated with multiple myeloma in humans (Patients of African ancestry; comparison with MGUS) (Qualifying variants observed only in MM).

    “qualifying VWA5B2 variants observed only in MM within this cohort.”

    HumansPatients of African ancestry; comparison with MGUS

    Germline Genomic and DNA Methylation Differences Between MGUS and Multiple Myeloma Among Patients of African Ancestry

    Cells

More on VWA5B2

Selenomethionine

upin humans1

1 study
  1. Selenomethionine raises the risk of multiple myeloma in humans (post-intervention follow-up).

    “we found a higher risk for Hodgkin lymphoma, multiple myeloma and amyotrophic lateral sclerosis”

    Human trialpost-intervention follow-upL-selenomethionine200 μg7-12 yearsmalesn = 34,887

    The selenium and vitamin E cancer prevention trial (SELECT): a secondary, post-intervention analysis on potential excess chronic disease incidence induced by selenium administration

    American journal of epidemiology

More on Selenomethionine

SGLT2 inhibitors

downin humans1

1 study
  1. SGLT2 inhibitors are linked with a lower risk of multiple myeloma in humans (compared with DPP-4 inhibitor exposure) (HRs <= 0.37).

    “We observed SGLT2i compared with DDP4i exposure was associated with a reduced risk of MM in the general population (hazard ratios [HRs] ≤ 0.37, p < 0.001)”

    Humanscompared with DPP-4 inhibitor exposure

    SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma

    European journal of haematology

More on SGLT2 inhibitors

NANOG and OCT4 expression

downin human cells1

1 study
  1. Multiple myeloma is associated with NANOG and OCT4 expression in human cells (compared with normal donor MSCs).

    “NANOG and OCT4 were significantly downregulated.”

    Cellscompared with normal donor MSCs

    Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches

    Blood research

More on NANOG and OCT4 expression

P21 and IL-6 expression

upin human cells1

1 study
  1. Multiple myeloma is associated with P21 and IL-6 expression in human cells (compared with normal donor MSCs).

    “Gene expression analysis showed upregulation of P21 and IL-6 in MM-MSCs”

    Cellscompared with normal donor MSCs

    Deregulation of stemness and senescence genes in bone marrow mesenchymal stem cells of multiple myeloma: implications for therapeutic approaches

    Blood research

More on P21 and IL-6 expression

All 34

Trial sponsors

Funding

30 grants since 2016

National Cancer Institute$15.8MUS Department of Veterans AffairsNational Institute on Aging$2M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 5Jan 2026: 17Feb 2026: 12Mar 2026: 13Apr 2026: 6May 2026: 5Jun 2026: 0Jul 2026: 8Aug 2026: 6Sep 2026: 5Oct 2026: 14Nov 2026: 9100 papers in 12 months
bioRxiv

Immune aging score linked to shorter myeloma survival

Among patients diagnosed before 70, accelerated immune aging was linked to shorter survival after clinical adjustments, with a hazard ratio of 2.24.Among patients diagnosed before 70, accelerated immune aging was linked to shorter survival after clinical adjustments, with a hazard ratio of 2.24.

Preprint: cohort studyMultiple myeloma
medRxiv

Rare gene variants linked to benign fat and uterine tumors

People carrying disabling variants in TERF1, a chromosome-protection gene, had 3.32 times the odds of benign fatty tumors compared with people without those variants.People carrying disabling variants in TERF1, a chromosome-protection gene, had 3.32 times the odds of benign fatty tumors compared with people without those variants.

Preprint: genetic association · 459,449 peoplePopulations

See all 309 papers on multiple myeloma